DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Clinical Trials
808
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (753 trials with phase data)• Click on a phase to view related trials
LASER - a Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for Renal Cell Carcinoma
- Conditions
- Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaKidney Cancer
- Interventions
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT06964958
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ACT Lung Health Intervention: Phase Two
- Conditions
- Smoking CessationSmoking BehaviorsSmoking, TobaccoSmoking, CigaretteSmoking (Tobacco) Addiction
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 128
- Registration Number
- NCT06945120
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
BOLSTER: Learning New Skills to Thrive
- Conditions
- Gastrointestinal CancerGynecologic CancerAdvanced Cancer
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 600
- Registration Number
- NCT06936878
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
- Conditions
- LymphomaLymphoma, HodgkinLymphoma, Non-HodgkinSedentary Behavior
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT06923397
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
- Conditions
- Acute LeukemiaLeukemia
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 75
- Registration Number
- NCT06907797
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 162
- Next
News
Modified NeoVax Cancer Vaccine Shows Enhanced Immune Response in Melanoma Patients
Dana-Farber researchers developed NeoVaxMI, an improved version of their personalized cancer vaccine that demonstrated enhanced immune responses in all nine melanoma patients tested.
Psychedelic Therapy Expands Beyond Cancer Care as Multi-Center Studies Launch
Sunstone Therapies has conducted over 150 MDMA sessions through expanded access programs, demonstrating the drug's relational properties that facilitate therapeutic conversations and empathy.
TRUST Trial Shows Primary Surgery Improves Progression-Free Survival in Advanced Ovarian Cancer Despite Missing Overall Survival Endpoint
The TRUST trial, the first phase III randomized study comparing surgical timing in advanced ovarian cancer, demonstrated statistically significant improvement in progression-free survival with primary cytoreductive surgery versus interval surgery (22.1 vs 19.7 months, HR=0.80, P=.018).
First-in-Class CBP/p300 Inhibitor TT125-802 Shows Promise in Treatment-Resistant NSCLC
TT125-802, a novel oral CBP/p300 bromodomain inhibitor, demonstrated early clinical activity in advanced solid tumors with a favorable safety profile in an ongoing phase 1 trial.
Dr. Elizabeth Mittendorf Outlines Vision as ASCO President-Elect to Advance Multidisciplinary Cancer Care and Workforce Support
Dr. Elizabeth Mittendorf, the 2026-2027 ASCO President-Elect, will focus on advancing multidisciplinary collaboration, broadening clinical trial access, and strengthening oncology workforce support during her presidency.
Leon-nanodrugs Appoints Dr. Wolfgang Hofmann as CEO to Drive Nanoparticle Manufacturing Technology Commercialization
Munich-based leon-nanodrugs GmbH has appointed Dr. Wolfgang Hofmann as CEO to lead the company's transition from development to commercialization of its FR-JET® nanoparticle manufacturing technology.
AMPLITUDE Trial Shows Niraparib Combination Reduces Cancer Progression Risk by 37% in HRR-Mutant Metastatic Prostate Cancer
The phase III AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improved radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer harboring HRR gene alterations.
Trastuzumab Deruxtecan Combination Reduces Disease Progression Risk by 44% in HER2-Positive Metastatic Breast Cancer
A new treatment combining trastuzumab deruxtecan (T-DXd) with pertuzumab reduced the risk of disease progression or death by 44% compared to standard care in HER2-positive metastatic breast cancer patients.
RLY-2608 Shows Promise in PIK3CA-Mutant Breast Cancer with Improved Tolerability Profile
RLY-2608, a mutant-selective PI3Kα inhibitor, combined with fulvestrant achieved a 38.7% overall response rate and 10.3-month median progression-free survival in patients with PIK3CA-mutant HR+/HER2- advanced breast cancer.
DLL3-Targeted CAR-T Therapy LB2102 Shows Promise in Relapsed/Refractory Small Cell Lung Cancer
LB2102, a DLL3-directed autologous CAR-T cell therapy, demonstrated preliminary antitumor activity with a 16.7% objective response rate and 66.7% disease control rate in patients with relapsed/refractory small cell lung cancer and large cell neuroendocrine carcinoma.